rilpivirine 600 MG in 2 ML Extended Release Injection

RxCUI: 2594982
RxNorm name: rilpivirine 600 MG in 2 ML Extended Release Injection
Display name: rilpivirine 600 MG in 2 ML Extended Release Injection
Full name: rilpivirine 600 MG in 2 ML Extended Release Injection
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:38:48

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Cabenuva	CABOTEGRAVIR AND RILPIVIRINE	ViiV Healthcare Company	1698baf3-f895-4c42-a1b1-e9ee3f20da36	2025-11-26	Warnings, Adverse reactions	Exact identifier rxcui: 2594982

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
1698baf3-f895-4c42-a1b1-e9ee3f20da36	rilpivirine 600 MG in 2 ML Extended Release Injection	PSN	16	These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use Initial U.S. Approval: 2021	20251126
1698baf3-f895-4c42-a1b1-e9ee3f20da36	rilpivirine 600 MG per 2 ML Injection	SY	16	These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use Initial U.S. Approval: 2021	20251126
1698baf3-f895-4c42-a1b1-e9ee3f20da36	2 ML rilpivirine 300 MG/ML Injection	SCD	16	These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use Initial U.S. Approval: 2021	20251126